Core Viewpoint - Castle Biosciences, Inc. is expected to report a year-over-year increase in earnings and revenues for the quarter ended December 2024, with significant attention on how actual results compare to consensus estimates [1][2]. Earnings Expectations - The upcoming earnings report is anticipated to be released on February 27, 2025, with a consensus EPS estimate of 85.75 million, which is a 29.7% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 86.79% higher in the last 30 days, indicating a significant reassessment by analysts [4]. - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likelihood of actual earnings deviating from consensus estimates, with a strong predictive power for positive readings [7][8]. - Castle Biosciences currently holds a Zacks Rank of 2 (Buy), but the combination with an Earnings ESP of 0% makes it challenging to predict an earnings beat [11]. Historical Performance - In the last reported quarter, Castle Biosciences exceeded the consensus EPS estimate by delivering earnings of 0.06 was expected, resulting in a surprise of +233.33% [12]. - The company has successfully beaten consensus EPS estimates in the last four quarters [13]. Market Context - The broader industry context includes Regenxbio, which is expected to report a loss of 22.3 million, a slight increase of 0.4% from the previous year, with a consensus EPS estimate revised 20.4% higher recently [18].
Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth